SAN DIEGO — Anitocabtagene autoleucel exhibited durable efficacy among heavily pretreated patients with high-risk relapsed or refractory multiple myeloma, results of the phase 2 iMMagine-1 study showed.
Anitocabtagene autoleucel (Arcellx Inc. and Kite Pharma/Gilead Sciences) — often called anito-cel — also exhibited a manageable safety profile, according to researchers who presented the findings at ASH Annual Meeting and Exposition.
“The data from the iMMagine-1 study demonstrate that this is a highly active product with impressive depth of responses achieved in patients